N-[5-(4-hydroxyphenyl)pyridin-3-yl]-2,5-dimethoxybenzenesulfonamide | 1451271-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[5-(4-hydroxyphenyl)pyridin-3-yl]-2,5-dimethoxybenzenesulfonamide
• 英文别名: US10370333, Example III-7
• CAS: 1451271-56-9
• 化学式: C₁₉H₁₈N₂O₅S
• 分子量: 386.428
• InChiKey: QXGILCHEBAWWKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS<br/>[FR] COMPOSÉS SULFONAMIDES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE TNAP
  申请人：SANFORD BURNHAM MED RES INST

  公开号：WO2013126608A1

  公开（公告）日：2013-08-29

  Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper- mineralization.

  本发明描述了调节TNAP活性的化合物。在某些实施例中，本发明描述的化合物抑制TNAP。在某些实施例中，本发明描述的化合物可用于治疗与过度矿化相关的病症。
• SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS
  申请人：Sanford-Burnham Medical Research Institute

  公开号：US20150011551A1

  公开（公告）日：2015-01-08

  Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.

  本文描述了调节TNAP活性的化合物。在某些实施例中，所述化合物抑制TNAP。在某些实施例中，所述化合物对于治疗与高矿化相关的疾病是有用的。
• Sulfonamide compounds and uses as TNAP inhibitors
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10370333B2

  公开（公告）日：2019-08-06

  Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.

  本文所述化合物可调节 TNAP 的活性。在某些实施方案中，本文所述化合物可抑制 TNAP。在某些实施方案中，本文所述化合物可用于治疗与过度矿化相关的疾病。
• Control of chronic neuropathic pain and allodynia
  申请人：STC.UNM

  公开号：US10548994B1

  公开（公告）日：2020-02-04

  In one embodiment, the invention provides a method of treating a subject suffering from chronic neuropathic pain and/or allodynia by administering a therapeutically-effective amount of at least one LFA1 antagonist to the subject. In a preferred embodiment, the invention provides a method of treating a subject suffering from chronic neuropathic pain and/or allodynia, the method comprising administering intrathecally to the subject a therapeutically-effective amount of microparticles comprising PLGA-encapsulated pDNA-IL-10, optionally in combination with a therapeutically-effective amount of intrathecally-administered CpG oligodeoxynucleotide (CpG ODN) and/or at least one LFA1 antagonist.

  在一个实施方案中，本发明提供了一种治疗患有慢性神经病理性疼痛和/或异感症的受试者的方法，该方法通过向受试者施用治疗有效量的至少一种LFA1拮抗剂。在一个优选的实施方案中，本发明提供了一种治疗患有慢性神经病理性疼痛和/或异感症的受试者的方法，该方法包括向受试者经鞘内给药治疗有效量的微颗粒，该微颗粒包含PLGA包封的pDNA-IL-10，可选地与治疗有效量的经鞘内给药的CpG寡脱氧核苷酸（CpG ODN）和/或至少一种LFA1拮抗剂结合使用。
• CRLF-2 BINDING PEPTIDES, PROTOCELLS AND VIRAL-LIKE PARTICLES USEFUL IN THE TREATMENT OF CANCER, INCLUDING ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
  申请人：STC. UNM

  公开号：US20150010475A1

  公开（公告）日：2015-01-08

  The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by CRLF-2 and CD 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing CRLF-2 and CD 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (ALL), including (B-precursor acute lymphoblastic leukemia (B-ALL). Novel CRLF-2 binding peptides and CLRF-2 and CD19-binding viral-like particles (VLPs) useful in the treatment of cancer, including ALL are also provided.